ClinicalTrials.gg
CompletedNCT01528787Updated Apr 18, 2018Results posted

Study of AR-13324 in Patients With Elevated Intraocular Pressure

A Phase 2 interventional study of AR-13324 Ophthalmic Solution 0.01% and AR-13324 Ophthalmic Solution 0.02% in Ocular Hypertension and Open Angle Glaucoma, sponsored by Aerie Pharmaceuticals. Completed at 11 sites in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2018-04-18.

Primary conditionGlaucoma, Open-AngleRegistry: Ocular HypertensionReclassifiedWhy we changed it
Registry
Ocular Hypertension — the first condition term the registry derived for this study.
ClinicalTrials.gg
Glaucoma, Open-Angle
Why
  1. The study's listed conditions name Glaucoma, Open-Angle, a narrower term within Ocular Hypertension.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Aerie Pharmaceuticals (part of Alcon) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
85
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing netarsudil in Glaucoma, Open-Angle — 3 open to participants now, 4 under way, none of them phase 3. netarsudil · Glaucoma, Open-Angle.

Enrollment
9th of 17
85 · median 85
Started
2012
with 1 other
Phase 2
6 of 17
none open now
Registered
1st of 17
by date
Lead sponsor
11 of 17
Aerie Pharmaceuticals

Among the 17 studies testing netarsudil in Glaucoma, Open-Angle, this one is the 9th largest by enrollment, is one of 2 that started in 2012, is one of 6 in phase 2, and was the 1st registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 116 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

3 of the 17 studies testing netarsudil in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About netarsudil

netarsudil: first FDA approval 2017 (RHOPRESSA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 83 Glaucoma, Open-Angle studies recruiting now, 64 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing netarsudil in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

In this double-masked, vehicle-controlled, dose-response study, subjects will be randomized to receive AR-13324 Ophthalmic Solution 0.01%, 0.02%, and 0.04% or its vehicle (one eye), once daily (QD)in the morning (AM) for 7 days. The first dose and last dose will be administered in the clinic. Ocular safety and ocular hypotensive efficacy will be evaluated in the clinic throughout the study.

03

Conditions studied

  • Ocular Hypertension
  • Open Angle Glaucoma

Browse trials for

Keywords

  • Intraocular pressure
  • visual field
  • Ocular hypertension or open angle glaucoma
04

In context

Glaucoma, Open-Angle Reclassified

924 studies on the registry are indexed under Glaucoma, Open-Angle; 116 are open to participants now.

This study's enrollment of 85 is close to the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.

Browse Glaucoma, Open-Angle studies →

Lead sponsor

Aerie Pharmaceuticals is the lead sponsor of 36 studies on the registry; none are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.

First submitted before Aerie Pharmaceuticals became part of Alcon.

Compared within Glaucoma, Open-Angle, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Ocular Hypertension. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years of age or greater. 18 years of age or greater.
  2. Diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT).
  3. Unmedicated (post-washout, p.r.n.) IOP ≥ 24 mm Hg in one or both eyes at 08:00 hours, ≥ 21 mm Hg at 10:00, 12:00 and 16:00 hours on post-washout measurement (Visit 1).
  4. Corrected visual acuity in each eye +1.0 logMAR or better by ETDRS in each eye (equivalent to 20/200).
  5. Able and willing to give signed and follow study instructions.

Exclusion criteria

Exclusion Criteria:

Ophthalmic: Either eye

  1. Intraocular pressure > 36 mm Hg
  2. Known to any component of the formulation or to topical anesthetics, (benzalkonium chloride, etc.)
  3. Ocular trauma within the past six months, or ocular surgery or laser treatment within the past three months.
  4. Evidence of ocular infection, inflammation, blepharitis or conjunctivitis at baseline (Visit 1), or history of herpes simplex keratitis.
  5. Contact lens wear within 30 minutes of instillation of study medication.
  6. Ocular medication of any kind within 30 days of Visit 2, with the exception of a) ocular hypotensive medications (which must be washed out according to the provided schedule), b) lid scrubs (which may be used prior to, but not after Visit 2) or c) lubricating drops for dry eye (which may be used throughout the study),
  7. Clinically significant ocular disease (e.g. corneal edema, uveitis, severe keratoconjunctivitis sicca) which might interfere with the study, including glaucomatous damage so severe that washout of ocular hypotensive medications for one month is not judged safe (e.g., advanced glaucomatous optic nerve head or visual field loss).
  8. Any abnormality preventing reliable applanation tonometry in either eye. Study eye:
  9. Glaucoma: pseudoexfoliation or pigment dispersion component, history of acute angle-closure glaucoma, or closed or narrow angle upon gonioscopy. Note: Previous laser peripheral iridotomy is NOT acceptable.
  10. Previous glaucoma intraocular surgery or laser procedures such as argon laser trabeculoplasty (), selective laser trabeculoplasty (SLT) or micropulse laser trabeculoplasty ( MLT), as well as refractive procedures such as radio keratotomy (RK), laser eye surgery (LASIK), photorefractive keratectomy (PRK), or collagen cross linking.
  11. Central corneal thickness greater than 600 μm.

    General/Systemic:

  12. Clinically significant abnormalities in laboratory tests at screening, recognizing that subjects are not fasting at the time of drawing blood.
  13. Clinically significant systemic disease (e.g., uncontrolled diabetes, myasthenia gravis, hepatic, renal, cardiovascular or endocrine disorders) which might interfere with the study.
  14. Participation in any study within the past 30 days.
  15. Changes of systemic medication during the study that could have a substantial effect on IOP within 30 days prior to screening, or anticipated during the study.
  16. Due to status of preclinical safety program, women of who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of . An adult woman is considered to be of childbearing potential unless she is one year or three months post-surgical sterilization. All females of childbearing potential must have a negative urine pregnancy test result at the screening examination and must not intend to become pregnant during the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
85 participants (actual)

Study arms

  • Experimental
    AR-13324 Ophthalmic Solution 0.01%

    1 drop to study eye once daily

    Drug: AR-13324 Ophthalmic Solution 0.01%

  • Experimental
    AR-13324 Ophthalmic Solution 0.02%

    1 drop to study eye once daily

    Drug: AR-13324 Ophthalmic Solution 0.02%

  • Experimental
    AR-13324 Ophthalmic Solution 0.04%

    1 drop to study eye once daily

    Drug: AR-13324 Ophthalmic Solution 0.04%

  • Placebo comparator
    AR-13324 Ophthalmic Solution Vehicle

    1 drop to study eye once daily

    Other: AR-13324 Ophthalmic Solution Vehicle

Interventions

07

What researchers measure

Primary outcomes

  1. Intraocular Pressure (IOP)

    The primary efficacy outcome was the mean IOP across subjects within treatment group at each post-treatment timepoint of Day 8. Instillation of study treatment commenced on Day 2 following measurement of IOP. IOP was measured at 0800, 1000, 1200 and 1600 hours on days 2 and 8. IOP was also measured at 0800 hours on Day 4.

    Time frame: Study treatment was administered for 7 days; starting on Day 2 and ending on Day 8.

08

Results

Posted Feb 22, 2018

Participant flow

Participant flow — Overall Study
MilestoneAR-13324 Ophthalmic Solution 0.01%AR-13324 Ophthalmic Solution 0.02%AR-13324 Ophthalmic Solution 0.04%AR-13324 Opththalmic Solution Vehicle
Started22211923
Completed22211822
Not completed0011
Withdrew: Withdrawal by subject0001
Withdrew: Family emergency0010

Outcome measures

PrimaryIntraocular Pressure (IOP)

The primary efficacy outcome was the mean IOP across subjects within treatment group at each post-treatment timepoint of Day 8. Instillation of study treatment commenced on Day 2 following measurement of IOP. IOP was measured at 0800, 1000, 1200 and 1600 hours on days 2 and 8. IOP was also measured at 0800 hours on Day 4.

Time frame:
Study treatment was administered for 7 days; starting on Day 2 and ending on Day 8.
Reported as:
Mean · mmHg
Intraocular Pressure (IOP)
mmHgAR-13324 Ophthalmic Solution 0.01%AR-13324 Ophthalmic Solution 0.02%AR-13324 Ophthalmic Solution 0.04%AR-13324 Ophthalmic Solution Vehicle
Day 2, 0800 hours25.80 ± 3.69926.02 ± 2.54226.50 ± 3.35825.17 ± 2.980
Day 2, 1000 hours22.45 ± 3.71322.10 ± 3.14924.29 ± 5.34722.87 ± 2.681
Day 2, 1200 hours21.93 ± 2.99721.95 ± 3.65325.00 ± 5.29222.91 ± 2.863
Day 2, 1600 hours20.70 ± 3.52120.88 ± 3.46722.29 ± 4.84921.41 ± 3.110
Day 4, 0800 hours21.32 ± 4.04921.00 ± 4.53022.00 ± 5.35223.98 ± 3.730
Day 8, 0800 hours20.82 ± 5.48720.60 ± 3.49120.44 ± 3.93324.34 ± 3.663
Day 8, 1000 hours18.20 ± 4.16518.71 ± 3.20819.42 ± 3.66322.34 ± 4.034
Day 8, 1200 hours17.57 ± 4.25517.88 ± 3.45718.78 ± 4.48621.93 ± 3.818
Day 8, 1600 hours17.68 ± 3.16116.88 ± 3.04917.83 ± 3.51021.52 ± 4.244

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AR-13324 Ophthalmic Solution 0.01%0/22 (0%)0/22 (0%)12/22 (54.5%)
AR-13324 Ophthalmic Solution 0.02%0/21 (0%)0/21 (0%)15/21 (71.4%)
AR-13324 Ophthalmic Solution 0.04%0/19 (0%)0/19 (0%)17/19 (89.5%)
AR-13324 Ophthalmic Solution Vehicle0/23 (0%)0/23 (0%)1/23 (4.3%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventAR-13324 Ophthalmic Solution 0.01%AR-13324 Ophthalmic Solution 0.02%AR-13324 Ophthalmic Solution 0.04%AR-13324 Ophthalmic Solution Vehicle
Conjunctival HyperaemiaEye disorders11/2212/2114/191/23
Ocular HyperaemiaEye disorders1/221/213/190/23
Instillation Site ReactionGeneral disorders0/220/212/190/23
Vision BlurredEye disorders0/222/211/190/23
Dry EyeEye disorders0/222/210/190/23
Corneal StainingInvestigations0/222/211/190/23
Erythema of EyelidEye disorders0/221/211/190/23
DiplopiaEye disorders0/220/211/190/23
Vitreous FloatersEye disorders0/220/211/190/23
Blood Glucose IncreasedInvestigations0/221/211/190/23

Baseline characteristics

Age, Continuous
Age, Continuous(years)AR-13324 Ophthalmic Solution 0.01%AR-13324 Ophthalmic Solution 0.02%AR-13324 Ophthalmic Solution 0.04%AR-13324 Ophthalmic Solution VehicleTotal
Mean63.6 ± 12.3669.1 ± 8.6966.1 ± 11.0957.8 ± 12.2764.0 ± 11.83
Sex: Female, Male
Sex: Female, Male(Participants)AR-13324 Ophthalmic Solution 0.01%AR-13324 Ophthalmic Solution 0.02%AR-13324 Ophthalmic Solution 0.04%AR-13324 Ophthalmic Solution VehicleTotal
Female1414101351
Male8791034
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AR-13324 Ophthalmic Solution 0.01%AR-13324 Ophthalmic Solution 0.02%AR-13324 Ophthalmic Solution 0.04%AR-13324 Ophthalmic Solution VehicleTotal
Hispanic or Latino412411
Not Hispanic or Latino1820171974
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AR-13324 Ophthalmic Solution 0.01%AR-13324 Ophthalmic Solution 0.02%AR-13324 Ophthalmic Solution 0.04%AR-13324 Ophthalmic Solution VehicleTotal
American Indian or Alaska Native00000
Asian11013
Native Hawaiian or Other Pacific Islander00000
Black or African American13228
White2017172074
More than one race00000
Unknown or Not Reported00000
09

Study locations

11 sites
  • Aesthetic Eye Care Institute
    Newport Beach, California 92657, United States
  • Robert Noecker, M.D., M.B.A.
    Fairfield, Connecticut 06824, United States
  • Coastal Research Associates, LLC
    Roswell, Georgia 30076, United States
  • Heart of America Eye Care, P.A.
    Shawnee Mission, Kansas 66204, United States
  • Comprehensive Eye Care
    Saint Louis, Missouri 63090, United States
  • Rochester Ophthalmology Group
    Rochester, New York 14618, United States
  • The Eye Institute
    Tulsa, Oklahoma 74104, United States
  • Wills Eye Hospital
    Philadelphia, Pennsylvania 19107, United States
  • Univ Eye Surgeons, Maryville Ctr.
    Maryville, Tennessee 37803, United States
  • Texan Eye
    Austin, Texas 78731, United States
  • Medical Center Ophthalmology Associates
    San Antonio, Texas 78240, United States
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2012, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2018, 5 years 7 months after primary completion. A results delay was requested in Feb 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2012
First posted
Feb 8, 2012
Start
Mar 2012
Primary completionActual
Jul 2012
CompletionActual
Jul 2012
Results delay requested
Feb 17, 2014
Results first posted
Feb 22, 2018
Last update
Apr 18, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01528787
Responsible party
Sponsor
First posted
Feb 8, 2012
Start date
Mar 2012
Primary completion
Jul 2012
Completion
Jul 2012
Results posted
Feb 22, 2018
Last update
Apr 18, 2018

Study contacts

Theresa Heah, MD
study director · Aerie Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Netarsudil

Start the discussion